The reaffirmation of an Outperform rating and a $10 price target by a reputable analyst like Jay Olson from Oppenheimer could instill confidence among investors and potentially lead to a positive short-term impact on Sutro Biopharma's stock price. Analyst ratings, especially from well-regarded financial institutions, can significantly influence investor sentiment and stock prices.